These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37565064)

  • 21. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
    Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
    Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders.
    Mafuru M; Wu S; He S; Lu X; Huang J; Jiang H
    J Clin Pharmacol; 2019 Oct; 59(10):1340-1350. PubMed ID: 30997931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
    Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
    Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity.
    Dolton MJ; McLachlan AJ
    Int J Antimicrob Agents; 2014 Sep; 44(3):183-93. PubMed ID: 25106074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis.
    Chuwongwattana S; Jantararoungtong T; Chitasombat MN; Puangpetch A; Prommas S; Dilokpattanamongkol P; Watcharananan SP; Sukasem C
    Drug Metab Pharmacokinet; 2016 Apr; 31(2):117-22. PubMed ID: 26861072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined Effect of
    Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
    Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
    Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
    Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
    Hu L; Huang Q; Huang S; Feng Z
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
    Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
    Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
    Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
    Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
    Du YX; Zhu YX; Li L; Yang J; Chen XP
    Pharmacogenet Genomics; 2024 Aug; 34(6):191-198. PubMed ID: 38747453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes.
    Niioka T; Fujishima N; Abumiya M; Yamashita T; Ubukawa K; Nara M; Fujishima M; Takahashi N; Miura M
    Ther Drug Monit; 2017 Oct; 39(5):514-521. PubMed ID: 28834922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voriconazole plasma concentrations and dosing in paediatric patients below 24 months of age.
    Gastine SE; Rauwolf KK; Pieper S; Hempel G; Lehrnbecher T; Tragiannidis A; Groll AH
    Mycoses; 2023 Nov; 66(11):969-976. PubMed ID: 37553971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
    Sienkiewicz B; Urbaniak-Kujda D; Dybko J; Dryś A; Hurkacz M; Wróbel T; Wiela-Hojeńska A
    Pathol Oncol Res; 2018 Jul; 24(3):541-545. PubMed ID: 28685218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interpersonal Factors in the Pharmacokinetics and Pharmacodynamics of Voriconazole: Are CYP2C19 Genotypes Enough for Us to Make a Clinical Decision?
    Zhong X; Tong X; Ju Y; Du X; Li Y
    Curr Drug Metab; 2018; 19(14):1152-1158. PubMed ID: 29361899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
    Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.
    Espinoza N; Galdames J; Navea D; Farfán MJ; Salas C
    Sci Rep; 2019 Jun; 9(1):8863. PubMed ID: 31222084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.